EUGENE R BLEECKER ET AL: "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting &bgr;2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial", LANCET, vol. 388, no. 10056, 1 October 2016 (2016-10-01), pages 2115-2127, XP055342068, AMSTERDAM, NL ISSN: 0140-6736, DOI: 10.1016/S0140-6736(16)31324-1 (B1)

GHAZI AASIA ET AL: "Benralizumab--a humanized mAb to IL-5R[alpha] with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 12, no. 1, 1 January 2012 (2012-01-01), pages 113-118, XP009159038, ISSN: 1744-7682, DOI: 10.1517/14712598.2012.642359 (B1)

MICHEL LAVIOLETTE ET AL: "Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 132, no. 5, 16 July 2013 (2013-07-16) , pages 1086-1096.e5, XP055277773, AMSTERDAM, NL ISSN: 0091-6749, DOI: 10.1016/j.jaci.2013.05.020 (B1)

WO-A2-2013/066780 (B1)

N. A. MOLFINO ET AL: "Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor", CLINICAL & EXPERIMENTAL ALLERGY, vol. 42, no. 5, 1 May 2012 (2012-05-01), pages 712-737, XP055026155, ISSN: 0954-7894, DOI: 10.1111/j.1365-2222.2011.03854.x (B1)

WO-A1-2008/143878 (B1)

Merck: "Asthma Severity and Control Monitoring Guide", , 1 January 2007 (2007-01-01), XP055341967, Retrieved from the Internet: URL:http://www.kyaap.org/pdf/merck-severit y_control.pdf [retrieved on 2017-02-03] (B1)